Human papilloma virus e6/e7 oncoproteins specific TCR T-cell therapy - Juno Therapeutics

Drug Profile

Human papilloma virus e6/e7 oncoproteins specific TCR T-cell therapy - Juno Therapeutics

Alternative Names: HPV oncoproteins specific TCR T-cell therapy - Juno Therapeutics; TCR cell therapy targeting HPV oncoproteins e6/e7- Juno Therapeutics

Latest Information Update: 23 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Juno Therapeutics
  • Class Antineoplastics; Gene therapies; T lymphocyte cell therapies
  • Mechanism of Action Gene transference; Human papillomavirus E6 protein modulators; Human papillomavirus E7 protein modulators; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 23 Mar 2017 Juno Therapeutics plans a phase I trial for HPV-associated cancer in USA
  • 01 Mar 2017 Early research in Cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top